Clinical Trials Logo

Dermatitis, Exfoliative clinical trials

View clinical trials related to Dermatitis, Exfoliative.

Filter by:

NCT ID: NCT06444399 Not yet recruiting - Clinical trials for Pityriasis Rubra Pilaris

Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris

Start date: July 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.

NCT ID: NCT05144165 Recruiting - Psoriasis Clinical Trials

Systemic Treatment of Moderate-to-severe Psoriasis in Adults: Update of the French Guidelines

Start date: November 8, 2021
Phase:
Study type: Observational

French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults have been developed by the psoriasis research group of the French Society of Dermatology using literature available until July 2017 (Amatore et al, 2019). Because several systemic treatments have been marketed since then, new guidelines are mandatory. The aim of this study coordinated by the Centre of Evidence of the French Society of Dermatology is to update the available French guidelines using a Delphi method.

NCT ID: NCT04183881 Completed - Psoriatic Arthritis Clinical Trials

A Phase 4 Clinical Study of Brodalumab

Start date: July 4, 2016
Phase: Phase 4
Study type: Interventional

This study [4827-005 (post market)] is designed to evaluate the safety and efficacy of long-term exposure to brodalumab in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic arthritis) who have completed Study 4827-003 (Study 003) and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004). 4827-005 study was conducted as phase 3 clinical trial until July 4th 2016 (approval date in Japan). After that date 4827-005 study was switched to phase 4 study.

NCT ID: NCT03975153 Completed - Clinical trials for Pityriasis Rubra Pilaris

Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Start date: October 3, 2019
Phase: Phase 2
Study type: Interventional

15 patients with PRP will be treated with guselkumab for 20 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit, week-4 visit, and week-24 visit. 3 visits in between these times and one follow up visit may be performed by secure videoconferencing.

NCT ID: NCT03485976 Completed - Clinical trials for Pityriasis Rubra Pilaris

Ixekizumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Start date: May 23, 2018
Phase: Phase 2
Study type: Interventional

15 patients with PRP will be treated with ixekizumab for 24 weeks to determine safety and efficacy. Participants are required to travel to Portland, OR only for the first visit and week-24 visit. 5 visits in between these times and one follow up visit may be performed by secure videoconferencing.

NCT ID: NCT03342573 Completed - Clinical trials for PITYRIASIS RUBRA PILARIS

Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris

Start date: April 1, 2018
Phase: Phase 1
Study type: Interventional

The primary objective of this study is to assess the potential effectiveness of Cosentyx in the treatment of adult-onset Pityriasis Rubra Pilaris or PRP.

NCT ID: NCT03041038 Completed - Netherton Syndrome Clinical Trials

The Efficacy and Safety of Secukinumab in Patients With Ichthyoses

Start date: December 2016
Phase: Phase 2
Study type: Interventional

The ichthyoses are a group of lifelong genetic disorders which share characteristics of generalized skin thickening, scaling and underlying cutaneous inflammation. There are no therapies based on growing understanding of what causes the disease. However, there have been recent discoveries of marked elevations in expression of interleukin-17A (IL-17A) and IL-17-related cytokines in the skin of individuals with ichthyosis, which may explain the inflammation. Investigators propose that IL-17-targeting therapeutics will safely suppress the inflammation and possibly the other features of ichthyosis, improving quality of life.

NCT ID: NCT02052609 Completed - Psoriatic Arthritis Clinical Trials

A Phase 3 Clinical Study of KHK 4827

Start date: February 2014
Phase: Phase 3
Study type: Interventional

This study is designed to evaluate the safety and efficacy of long-term exposure to KHK4827 in subjects with plaque psoriasis (psoriasis vulgaris, psoriatic erythroderma) who have completed Study 4827-003 (Study 003)and in subjects with pustular psoriasis (generalized) or psoriatic erythroderma who have completed the Study 4827-004 (Study 004).

NCT ID: NCT00815633 Terminated - Clinical trials for Pityriasis Rubra Pilaris

A Pilot Study of Alefacept for the Treatment of Pityriasis Rubra Pilaris

Start date: December 2008
Phase: Phase 4
Study type: Interventional

The purpose of this study is to determine whether the biologic medication alefacept (Amevive) is effective and safe in the treatment of Pityriasis Rubra Pilaris.

NCT ID: NCT00748319 Completed - Dermatitis Clinical Trials

Killer Immunoglobulin-Like Receptor Transcripts Expression for the Diagnosis of Epidermotropic Cutaneous T Cell Lymphoma

KIR
Start date: March 2009
Phase: N/A
Study type: Interventional

The most frequent cutaneous T-cell lymphomas (CTCL) are mycosis fungoid and Sezary syndrome. The diagnosis of these lymphomas is difficult using current methods, especially because numerous benign dermatological conditions can mimick CTCL both clinically and under microscopic examination. Recently, the KIR receptor CD158k has been shown to be a marker for Sezary syndrome in both the blood and skin. We hypothesize that other receptors from the same family may help fro the diagnosis of these lymphomas. To address this issue, we will study the expression of all known KIR receptor in the skin of patients presenting with a skin eruption, which may correspond to either a cutaneous T-cell lymphoma or a benign dermatological disease. The final diagnosis will be established by a panel of experts, allowing constitution of 2 groups of patients : the cutaneous T-cell lymphoma group, and the benign inflammatory disease group. The expression of the different KIRs will be analyzed in both group in a blinded fashion, in order to determine whether one or a several KIRs may be differentially expressed.